Medical marijuana has been one of the most effective and versatile treatments for a variety of diseases for decades. Recently, a number of U.S. states added new conditions to their lists of acceptable illnesses to receive such treatments. In Minnesota, sleep apnea patients can now turn to medical marijuana. Michigan also updated its list to include an additional 11 health issues such as autism.
After soliciting public comments as well as reviewing the scientific evidence on hand, the Minnesota Department of Health decided to allow medical marijuana as a treatment for sleep apnea, KSTP reports. This decision was also made after a review panel by citizens was hosted to ensure that the local populace was onboard.
However, not everyone is thrilled about this decision, with some health experts stating that medical marijuana is not as effective in treating the condition as conventional medical treatments. Sleep apnea expert Dr. Jonathan Parker is one such voice to express concern that the development could lead to negative consequences.
Aside from Minnesota, Michigan also decided to update its list of acceptable medical conditions that could receive medical marijuana treatment. These conditions include Parkinson’s disease, chronic pain, and Tourette’s syndrome, the Detroit Free Press reports. The state even threw in autism into the mix for good measure.
In order to make use of medical marijuana, however, patients will need a medical marijuana card. The card must be approved by a doctor and will cost $60.
With these new diseases on the list, the items have now gone up to 22 acceptable ailments. However, even as the state approved the 11 health conditions, it also rejected 11 others. The diseases that were not deemed acceptable to receive medical marijuana treatment include depression, panic attacks, and asthma. That last part might have been the most understandable, however, since it is a respiratory condition.


Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
FDA Weighs Safety Standards for Psychedelic Therapies
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
France Keeps Top Health Alert as Officials Brace for Another Heatwave
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 



